Selank and Serotonin: Neurotransmitter Effects
Selank
84 Genes
Number of neurotransmission-related genes with altered expression in rat frontal cortex after selank administration, spanning GABA, serotonin, and dopamine systems.
Filatova et al., Frontiers in Pharmacology, 2017
Filatova et al., Frontiers in Pharmacology, 2017
View as imageMost anxiolytic drugs target one neurotransmitter system. Benzodiazepines enhance GABA. SSRIs increase serotonin availability. Selank does something different: it modulates at least three major neurotransmitter systems simultaneously. Filatova et al. (2017) demonstrated that selank administration altered the expression of 84 genes involved in neurotransmission in the rat frontal cortex, spanning GABA receptor subunits, serotonin receptors, dopamine receptors, transporters, and ion channels.[1] This multi-system profile explains why selank produces anxiolytic effects without the sedation, amnesia, and dependence that characterize GABA-only drugs. For background on how selank modulates GABA specifically, the GABA article covers the receptor-level mechanisms. This article focuses on the broader neurotransmitter picture, particularly the serotonin and dopamine effects that distinguish selank from classical anxiolytics. The selank overview covers the full research landscape; here we go deeper into the neurotransmitter mechanisms.
Key Takeaways
- Selank altered expression of 84 neurotransmission genes in rat frontal cortex, including GABA, serotonin, and dopamine receptor subunits (Filatova et al., 2017)
- Selank enhances serotonin metabolism in the brain stem within 30 minutes of administration (Vyunova et al., 2018)
- The peptide inhibits enkephalin-degrading enzymes, prolonging endogenous opioid peptide activity (Zozulya et al., 2001)
- Functional brain connectivity studies showed selank affects neural networks in regions associated with attention and emotional regulation (Panikratova et al., 2020)
- Selank protected against ethanol-induced memory impairment by modulating neurotransmitter systems disrupted by alcohol (Kolik et al., 2019)
- Unlike benzodiazepines, selank produces no reported dependence, withdrawal, or amnesia despite similar anxiolytic potency at low doses (Vyunova et al., 2018)
A Tuftsin Derivative with Unexpected Reach
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analogue of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from IgG immunoglobulin. Tuftsin's known function is immune modulation, specifically enhancing phagocyte activity. By extending the tuftsin sequence with three additional amino acids (Pro-Gly-Pro), researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences created a peptide with both immune-modulating and neurotropic properties.
Kozlovskaya et al. (2003) were among the first to characterize selank's behavioral effects systematically, studying it alongside other short peptides of the tuftsin family in the regulation of adaptive behavior. They found that selank influenced learning, memory, and anxiety-related behaviors in animal models, suggesting activity beyond the immune system.[2] The immune function connection remains an active area of research and helps explain why selank's effects cross traditional pharmacological categories.
Serotonin: Enhanced Metabolism in the Brain Stem
Vyunova et al. (2018) published the most comprehensive review of selank's molecular mechanisms in a paper titled "Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity." They documented that selank enhances serotonin metabolism in the brain stem within 30 minutes of administration.[3]
The serotonin effect is not a simple increase in serotonin levels. Selank appears to modulate serotonin turnover, the rate at which serotonin is synthesized, released, and recycled. This is a fundamentally different mechanism than SSRIs, which block reuptake to increase serotonin in the synaptic cleft. Selank's serotonergic action is more modulatory than directional, adjusting the system's activity rather than forcing it in one direction.
Filatova et al. (2017) showed this at the gene expression level: selank altered the expression of serotonin receptor genes and serotonin transporter genes in the frontal cortex, suggesting the peptide reconfigures how the serotonin system operates rather than simply increasing or decreasing a single parameter.[1]
This may explain the clinical observation that selank reduces anxiety without the emotional blunting that SSRIs sometimes produce. If selank is modulating serotonin system dynamics rather than crudely increasing serotonin availability, the functional output would be more nuanced. The nootropic peptide landscape includes other peptides with serotonergic effects, but selank's multi-system profile is unusual even within that category.
GABA: Gene Expression Changes Across the System
The GABAergic effects of selank are the best characterized. Filatova et al. (2017) analyzed gene expression in IMR-32 neuroblastoma cells and found that selank affected genes encoding major GABA-A receptor subunits, GABA transporters, and GABA-metabolizing enzymes.[1] The pattern of changes resembled that produced by olanzapine (an antipsychotic) more than that of exogenous GABA alone, suggesting selank has a complex, indirect relationship with GABAergic neurotransmission.
Kasian et al. (2017) demonstrated that selank enhances the anxiolytic effect of diazepam in rats exposed to unpredictable chronic mild stress. When co-administered, the combination produced greater anxiety reduction than either compound alone.[4] This synergy is consistent with selank acting on the GABA system through a different mechanism than benzodiazepines. If both drugs enhanced GABA through the same pathway, co-administration would produce diminishing returns, not additive effects.
Vyunova et al. (2018) drew the comparison explicitly: selank's anxiolytic effects are similar to those of benzodiazepine tranquilizers at low doses, but without the amnesia, withdrawal, and dependence that characterize benzodiazepine use.[3] The selank vs benzodiazepines comparison covers this distinction in greater detail. The absence of dependence liability is one of selank's most clinically significant properties and likely reflects the multi-system nature of its mechanism: because it does not act solely through GABA-A receptor potentiation, removing it does not produce the same withdrawal effects.
Dopamine: Cross-Talk Between Systems
Selank's effects on the dopamine system are less extensively studied than its GABA and serotonin effects, but the gene expression data are clear. Filatova et al. (2017) documented changes in dopamine receptor gene expression in the frontal cortex alongside the serotonin and GABA changes.[1]
Meshavkin et al. (2006) provided behavioral evidence for dopaminergic involvement. They showed that selank's "depriming" effect on apomorphine-induced behavioral manifestations (apomorphine is a dopamine agonist) was blocked by naloxone, an opioid antagonist.[5] This finding is remarkable because it implies that selank's dopaminergic effects are mediated through the endogenous opioid system, not through direct dopamine receptor binding. The cross-talk between opioid, dopamine, and serotonin pathways under selank's influence represents a level of pharmacological complexity rarely seen in a seven-amino-acid peptide.
Slominsky et al. (2017) studied selank alongside the related peptide semax in a 6-OHDA-induced Parkinson's disease model in rats. Both peptides affected behavior in this dopamine-depleted model, with selank showing distinct effects on motor and non-motor symptoms that implicate dopaminergic modulation.[6]
The Enkephalin Connection
One of the earliest identified mechanisms for selank's activity involves the endogenous opioid system. Zozulya et al. (2001) demonstrated that selank inhibits enkephalin-degrading enzymes, effectively prolonging the activity of the body's own enkephalin peptides.[7] Enkephalins are endogenous opioids that modulate pain, mood, and stress responses.
Sokolov et al. (2002) confirmed this in a behavioral study, showing that selank's effects on behavioral reactions correlated with changes in plasma enkephalin-degrading enzyme activity.[8] By preventing the breakdown of enkephalins, selank effectively amplifies the body's own anxiolytic and mood-regulating opioid signaling without introducing an exogenous opioid.
This mechanism connects the serotonin, dopamine, and GABA effects into a coherent picture. Enkephalin signaling modulates all three of these neurotransmitter systems. By preserving enkephalin activity, selank may indirectly influence serotonin turnover, GABA receptor sensitivity, and dopamine release patterns simultaneously. The gene expression changes documented by Filatova et al. (2017) may represent downstream consequences of enhanced enkephalin signaling rather than direct effects of selank on each system independently.
Functional Brain Connectivity
Panikratova et al. (2020) used functional connectivity analysis to study selank and semax effects in human participants, providing some of the rare human neuroimaging data for either peptide. Selank affected neural network connectivity in brain regions associated with attention, emotional regulation, and executive function.[9]
This is consistent with the multi-system neurotransmitter profile. Brain regions involved in attention (prefrontal cortex, anterior cingulate) receive dense serotonergic, dopaminergic, and GABAergic projections. A peptide that modulates all three systems would be expected to alter functional connectivity in exactly these networks.
Alcohol and Memory: Applied Neurotransmitter Effects
Two studies from the Kolik group illustrate how selank's multi-system profile translates into functional outcomes.
Kolik et al. (2016) showed that selank inhibits ethanol-induced hyperlocomotion and prevents the development of behavioral sensitization to ethanol in rats.[10] Ethanol sensitization involves adaptations in dopamine and GABA systems, and selank's ability to prevent these adaptations supports its multi-system mechanism.
Kolik et al. (2019) demonstrated that selank protects against ethanol-induced memory impairment by modulating neurotransmitter systems disrupted by alcohol. The protective effect was attributed to selank's influence on both the opioid and monoaminergic (serotonin/dopamine) systems.[11] The selank clinical studies in generalized anxiety cover the human anxiety data, while these alcohol studies illustrate the broader neurochemical versatility.
Kozlovskii (2003) documented selank's optimizing action on conditioned active avoidance responses in rats, showing that the peptide improved cognitive performance under stress, not just in anxious conditions.[12] This cognitive enhancement under stress is consistent with simultaneous modulation of serotonin (mood), dopamine (motivation/reward), and GABA (arousal regulation). The fact that selank improves cognitive performance specifically under stress conditions, rather than in relaxed baseline states, suggests its neurotransmitter effects are state-dependent: the peptide appears to normalize disrupted systems rather than push healthy systems beyond their baseline.
Limitations of the Evidence
The selank neurotransmitter research has clear constraints that affect how confidently these findings can be applied.
Geographic concentration: Nearly all studies come from Russian research groups, many funded by the developers of the peptide or by Russian government grants supporting the same research network. Independent replication by Western laboratories is sparse. This does not invalidate the findings, but it does mean the typical scientific safeguard of independent replication is largely absent.
In vitro vs in vivo: The gene expression data from Filatova et al. (2017) come from a neuroblastoma cell line (IMR-32), not primary human neurons, which limits the translational relevance. Cell lines can behave differently from neurons in intact brain tissue, where other cell types, blood-brain barrier dynamics, and network effects all influence gene expression.
No direct human neurotransmitter measurement: Human data on selank's neurotransmitter effects are limited to the Panikratova et al. (2020) connectivity study and clinical anxiety trials. No human study has directly measured serotonin, dopamine, or GABA levels or turnover in the brain after selank administration. Techniques like PET imaging with serotonin or dopamine receptor ligands could address this gap but have not been applied to selank research.
Dose extrapolation: The animal studies use varying doses and routes of administration (intraperitoneal, intranasal, intravenous), making it difficult to determine which neurotransmitter effects occur at the doses used clinically in humans. The intranasal doses approved in Russia may not produce the same magnitude of brain stem serotonin changes observed in animal studies with systemic injection.
Regulatory status: Selank is approved as a nasal spray medication in Russia and several post-Soviet states for anxiety and cognitive enhancement. It has not undergone FDA-regulated clinical trials and is not approved for any indication in the United States, European Union, or most other Western regulatory jurisdictions. The neuropeptide Y stress resilience research offers a comparison point for how Western laboratories have studied similar anxiolytic neuropeptide mechanisms with more rigorous methodology.
The Bottom Line
Selank modulates serotonin, GABA, dopamine, and endogenous opioid systems simultaneously, based on gene expression data showing 84 neurotransmission genes affected in the frontal cortex and behavioral studies spanning anxiety, memory, and alcohol-related paradigms. The enkephalin-sparing mechanism may be the upstream driver that connects these downstream neurotransmitter effects. This multi-system profile produces anxiolytic effects without benzodiazepine-type dependence, but the evidence base is heavily concentrated in Russian research groups with limited independent replication.